Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Sector Update: Health Care Stocks Softer Late Afternoon
Top Midday Gainers
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Nvidia Slump Continues
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Atara Biotherapeutics Announces Board Appointment and Capital Raise
Express News | Atara Biotherapeutics Inc - Well Positioned to Execute on Tab-Cel U.S. Bla Approval and Advancement of ATA3219
Express News | Atara Biotherapeutics Inc - Further Strengthens Balance Sheet With Cash Runway Into 2027 Enabling Key Pipeline Readouts
Express News | Atara Biotherapeutics Announces $36 Million Registered Direct Offering
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
H.C. Wainwright analyst Robert Burns maintains $Atara Biotherapeutics(ATRA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -19
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
Mizuho Securities analyst Salim Syed upgrades $Atara Biotherapeutics(ATRA.US)$ to a buy rating, and adjusts the target price from $25 to $18.According to TipRanks data, the analyst has a success
Express News | Atara Biotherapeutics Inc : Mizuho Raises to Outperform From Neutral; Cuts Target Price to $18 From $25
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $13 Price Target